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Vitamin D related research continues to expand and theorise regarding its involvement in obesity,
as both hypovitaminosis D and obesity strike in pandemic proportions. Vitamin D plays an important
role in immune system through Vitamin D Receptors (VDR), which are transcription factors located
abundantly in the body. Due to this characteristic, it is potentially linked to obesity, which is a state
of inflammation involving the release of cytokines from adipose tissue, and exerting stress on other
organs in a state of positive energy balance. Research trials in the past couple of years and
systematic reviews from SCOPUS and MEDLINE will be discussed. The role of Vitamin D
throughout the lifespan (from fetal imprinting until older age), and in various other obesity mediated
chronic conditions shall be highlighted. Various mechanisms attributed to the inverse relationship of
Vitamin D and obesity are discussed with research gaps identified, particularly the role of
adipokines, epigenetics, calcium and type of adipose tissue.

Competing Interests: The authors have declared that no
competing interests exist.

Introduction
This study reviews articles available on
PUBMED, Scopus and Google using the following
search keywords: (Vitamin D OR Ergocalciferol OR
Cholecalciferol) AND (Leptin/ adiponectin/ VDR/
inflammation/ adiposity/ body fat/ weight). The search
was limited to articles in the English language until
June 2016. Selected articles were also used to
identify further relevant studies. Most relevant
research articles were included; usually, review
articles and meta-analysis to present an analysed
picture of clinical trials regarding relevant information.
Vitamin D is a micronutrient that is
categorically non-essential due to the endogenous
production in the body with the aid of specific
ultraviolet rays, but it has now become an essential
component of diet as Vitamin D deficiency now
engulfs the world as a pandemic [1]. This idea was
established many years ago as Vitamin D inadequacy
was observed even among people living closer the

equator [2]. Hence, regulations directing fortification of
food is either implemented or are under consideration
[3]. In the 2011 conference of Institute of Medicine
(IOM), the Recommended Dietary Allowance (RDA)
(average daily level of intake sufficient to meet the
nutrient requirements of nearly all (97%-98%) healthy
people) for Vitamin D was set at 600 IU/d for ages 170 years and 800 IU/d for ages 71 years and older [4].
According to the Institute of Medicine (IOM)
Committee, the scientific evidence supports the key
role of Vitamin D in skeletal health and extra-skeletal
health; however, the extra-skeletal health outcomes
are not yet consistent to establish a cause-and-effect
relationship [4]. Doses to treat and/or maintain Vitamin
D status are still subjective and research studying the
needs across different life spans and conditions
continue. Vitamin D status now conjoins many other
health conditions after the discovery of Vitamin D
binding proteins and their receptors in many tissues
[5]. Vitamin D binding receptors (VDR) are
transcription factor responsible for extensive biological
responses. It is shown to play a role in cell

_______________________________________________________________________________________________________________________________
526

http://www.mjms.mk/
http://www.id-press.eu/mjms/

Hamid Mehmood & Papandreou. An Updated Mini Review of Vitamin D and Obesity
______________________________________________________________________________________________________________________________

proliferation inhibition, cell maturation, immune
system, and possibly colonic, breast and prostate
cancer [6]. Vitamin D status is influenced by sun
exposure, adiposity, body composition, race/ethnicity,
and genetic factors, but these need elucidations
through research, as suggested by IOM [6].
Vitamin D deficiency has been historically
defined and recently recommended by the Institute of
Medicine (IOM) as a 25(OH)D of less than 20 ng/ml.
Vitamin D insufficiency has been defined as a
25(OH)D of 21–29 ng/ml. Vitamin D deficiency results
in abnormalities in calcium, phosphorus, and bone
metabolism. Specifically, vitamin D deficiency causes
a decrease in the efficiency of intestinal calcium and
phosphorus absorption of dietary calcium and
phosphorus, resulting in an increase in PTH levels.
Secondary hyperparathyroidism maintains serum
calcium in the normal range at the expense of
mobilising calcium from the skeleton and increasing
phosphorus wasting in the kidneys. The PTHmediated increase in osteoclastic activity creates local
foci of bone weakness and causes a generalised
decrease in bone mineral density (BMD), resulting in
osteopenia and osteoporosis. Phosphaturia caused by
secondary hyperparathyroidism results in a low
normal or low serum phosphorus level. This results in
an inadequate calcium-phosphorus product, causing a
mineralisation defect in the skeleton. This results in an
inadequate calcium-phosphorus product, causing a
mineralisation defect in the skeleton [7].
A major health issue linked with Vitamin D is
the growing obesity rate. World Health Organization
states that in 2014 more than 1.9 billion adults were
overweight, of which 600 million were obese.
According to the Global Burden of Disease report of
USA, the potentially avoidable risk factors to rising
disease burden included high BMI and physical
inactivity for the healthy years lost [8]. Healthy years
measure the expected number of years a person of a
certain age could live without disability or be free of
any activity limitation. Despite increased levels of
sufficient physical activity in male and female, only 9
countries experienced a decline in obesity rate in the
United States (with statistically insignificant results)
compared to increment in the rest of the counties in
obesity during 2001 and 2009 [8]. Systematic analysis
to study Global, regional and national prevalence of
overweight and obesity in children and adults 19802013 did not report any significant decline in rate over
the past 33 years, but only a slowdown in increase
rate of overweight and obesity was observed just in
developed countries [9]. This is not satisfactory, as it
indicates that an increasing obesity trend endures in
other countries. This demands special attention from
the public health sector to search and address socioeconomic implications in maintaining Vitamin D. To
explain the deficiency of this fat-soluble vitamin in
people with excessive adipocytes, the following
possible mechanisms have been suggested: lower
dietary intake; altered behavior that reduces

cutaneous synthesis, reduced synthetic capacity,
reduced intestinal absorption, altered metabolism, and
sequestration in adipose tissue [10,11]. However,
extensive research is needed to establish a causeeffect relationship and explain these factors under
various conditions, because Vanlint concluded in his
review that the evidence for vitamin D affecting fat
mass and distribution is not yet compelling, and it is
difficult to determine which effects are due to vitamin
D itself and which are mediated via calcium when
based on evidence from in vitro studies [11].
Finally, this article highlights how these public
health issues of Vitamin D with its immune-related
properties are associated with obesity, which is a
state of low-grade inflammation. Various gaps
identified by IOM committee is briefly reviewed, such
as, non-skeletal health outcomes, epigenetic role,
physiology and pathways of Vitamin D [4].
Researchers have previously reviewed data on this
topic, [12, 14, 15], but due to constant addition of
knowledge in this area we considered updating.
Unlike some previous articles, we have concentrated
on discussing Vitamin D and inflammatory properties
in obesity, and further supplemented suggested
mechanisms with clinical studies.

Obesity,
a
inflammation

state

of

low-grade

Ectopic fat storage, due to overflow from
adipose tissues upon fat overloading leads to the
formation of foam cells from macrophages that engulf
fat droplets during transportation or storage.
Macrophages phagocytize lipid droplets in weight loss
from adipocytes that could describe basic
inflammatory nature of adipocytes. Hyperplasia and
hypertrophy of adipocytes can cause mitochondrial
and endoplasmic stress, which during fat overloading
releases additional inflammatory cytokines other than
adipokines, attracting more macrophages. During
adipocytes hypertrophy TNF-α (Tumor Necrosis
Factor- alpha), IL-6 (Interleukin-6), IL-1β (Interleukin-1
Beta), PG-E2 (Prostaglandin E2) expression is
induced, adipocytes die and neutrophils, monocytes
and T-Cells are persistently activated. CRP is also
enhanced in the liver to respond to inflammatory
cytokines, amplifying the cytokines pro-inflammatory
effect. Hyperplastic adipocytes also induce genes
TNF-α,
interleukins
(IL)-1,
IL-6,
monocyte
chemoattractant protein-1 (MCP-1), and plasminogen
activator inhibitor-1 (PAI-1) due to hypoxia from
clustered formation, which are distant from the
vasculature. Macrophages embedded in adipocytes
phagocytize lipid droplets and engulf dead adipocytes
that burst from high lipid accumulation, releasing
reactive oxygen species and inducing further cellular
stress [16]. The unfolded protein response (UPR) to
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cope with Endoplasmic Reticulum (ER) stress
promotes NF-κB (nuclear factor kappa-B) and JNK (cJun N-terminal kinases) inflammatory pathways due to
increased protein demand such as in hyperglycemia,
or during accumulation of misfolded protein.
Excessive nutrient influx increases superoxide
production and reactive oxygen species by
mitochondria. The down-regulation of autophagy in
the liver of lipid droplets in hepatocytes associated
with obesity leads to accumulation of triglyceride, ER
stress and Insulin resistance [17].
Visceral or subcutaneous fat in obesityrelated inflammation is still questionable due to
variability in results. A study investigating
concentrations
of
pro-inflammatory
enzymes
presented higher concentration of IL-6 and IL-15
(Interleukin-15) in Subcutaneous Adipose Tissue
(SAT) synthesis compared to Visceral Adipose Tissue
(VAT). However, obesity was associated with VAT,
since IL-6 and IL-15 were significantly more in obese
individuals compared to normal-weight ones,
whereas, the cytokines difference was not significant
between two groups in SAT related cytokines
expression [18]. On the other hand, some studies do
suggest
increased
pro-inflammatory
cytokines
expression in SAT compared to VAT proposing its
contribution to meta-inflammation [18, 19]. In
conclusion, visceral fat compared to subcutaneous fat
may cause metabolic abnormalities by secreting
inflammatory adipokines, such as interleukin, tumour
necrosis factor-α, macrophage chemoattractant
protein-1, and resistin, which induce insulin resistance
and diabetes and Vitamin D metabolic abnormalities.

Role of Vitamin D in
suggested mechanisms

obesity

and

Research to explore the relationship between
Vitamin D and obesity gains interest, because studies
investigating obesity (a state of low-grade
inflammation) and Vitamin D (with its role in immunity)
indicate potential links. Many studies report changes
in Vitamin D status with BMI changes. A change in
serum Vitamin D levels as a function of
adiposity/weight loss was noted over 1-2 years [20,
21]. An inverse relationship between Vitamin D and
BMI was recognised in Mendelian randomization
analysis, [22] and a link with abdominal visceral or
subcutaneous adipose tissue was also recognised
[23, 24]. In a meta-Analysis of observational studies
up to April 2014 in PubMed/Medline, Vitamin D
deficiency was prevalent in obese subjects
irrespective of age, latitude and cut-offs defining
vitamin D deficiency [14].
Another meta-analysis of literature focusing
on the last 5 years proposed various mechanisms to

discern body weight and Vitamin D relationship, which
include: Vitamin D Receptor (VDR) polymorphism
shown in transgenic mice and its overexpression in
adipocytes that led to fatty acid β-oxidation, lipolysis
and
reduced
energy metabolism;
increased
parathyroid hormone levels in Vitamin D deficiency
that can increase adiposity by influx of calcium into
adipocytes promoting lipogenesis; Vitamin D as
“essential factor” in leptin depletion which may
contribute to increased appetite and obesity in Vitamin
D deficient conditions; and outdoor activity, food
intake and exercise which can also influence Vitamin
D levels as confounding factors [25].
Adipokines relationship with Vitamin D is
studied due to their role in obesity. In vitro leptin,
secretion by adipose tissue is powerfully inhibited by
Vitamin D deficiency [12]. Although clinical trials
showed an increase in serum leptin with Vitamin D
supplementation, [26, 27] the clinical significance
remains to be asserted [12, 28]. A significant effect of
Vitamin D supplementation on adiponectin and leptin
was not observed in a meta-analysis of 9 Randomized
Controlled Trials (RCT) [29]. Serum changes in
Vitamin D were significantly associated with plasma
leptin levels, independent of plasma adiponectin
concentrations. Further larger clinical trials and metaanalysis to effectively review these adipokines,
especially focusing on obesity, are needed, as more
meta-analysis could not be found.
The dose-response relationship between
serum Vitamin D levels have changed and BMI
showed a quadratic curve in a research involving
various Vitamin D3 doses that suggested rate-limiting
mechanism to avoid excessive formation of 1,25(OH)2D3 (the active metabolite) [30]. The doseresponse curves, although parallel, were noted for
their difference between the curves, which was
approximately 17.5 nmol/L lower for obese subjects
compared to normal ones, and approximately
12.5nmol/L lower levels in overweight compared to
normal-weight subjects. Extracellular pool size was
suggested as the potential factor in this discrepancy
rather than fat [29].
Vitamin
D-metabolizing
enzymes
are
expressed differently in Adipose tissue as well. There
was decreased expression of the 25-hydroxylase
CYP2J2 and the 1α-hydroxylase CYP27B1 (which
converts 25(OH)D3 to the active 1,25(OH)2D3) in
Subcutaneous adipose tissue, and increased
expression of CYP24A1 (which inactivates calcitriol
binding and activating VDR) after weight loss [30].
Calcium-sensing receptors (CaSR) gene and
protein expression were found similar in white adipose
tissue of obese and control mice group. Obese group
had lower serum vitamin D and amino acid
concentrations, and significantly higher serum
triglyceride (TG), total cholesterol (TC), low-density
lipoprotein-cholesterol (LDL-C), TNF-α, IL-6 and PTH
levels, which suggests that Calcium-sensing receptors

_______________________________________________________________________________________________________________________________
528

http://www.mjms.mk/
http://www.id-press.eu/mjms/

Hamid Mehmood & Papandreou. An Updated Mini Review of Vitamin D and Obesity
______________________________________________________________________________________________________________________________

function through allosteric regulation [31]. CaSR
elevates pro-inflammatory cytokines in adipose tissue
and decreases cyclic AMP, protein kinase An activity,
hormone-sensitive lipase and adipose triglyceride
lipase that are key players in the lipolytic pathway
[32]. Low Calcium-induced 1,25-di(OH)2D3 secretion
upregulates CaSR expression in adipose tissue,
which is followed by an increase in [Ca2+] and
reduced lipolysis, and possibly lipogenesis finally
yielding fat accumulation in adipocytes. It was shown
that higher BMI shows a greater increase in CaSR
protein and thus more pro-inflammatory cytokines
secreted from obese tissue [33].

Studies in relationship to Vitamin D and
obesity in general population
Obesity in adults is not only of concern for
their reduced productivity in life but it may also affect
new lives. Observational studies and animal studies
now propose and explore the mechanism about how
maternal BMI and offspring adiposity from an early
age are independently associated, and how in-utero
environmental exposures increase susceptibility
to obesity and are related to cardiometabolic disorders
in later life [34, 35]. An increased risk of prenatal and
st
early postnatal overweight in offspring (1 year of life)
was found, which was attenuated by 4 years of age
[36]. Vitamin D status during pregnancy could have an
epigenetic role since it is not only pivotal in maternal
skeletal maintenance and fetal skeletal development,
but it could influence fetal “imprinting”, which can
affect chronic disease susceptibility soon after birth
[37]. Decreased placental expression of VDR in the
placenta may be a contributing factor to the pathology
of idiopathic FGR (Fetal Growth Restricted)-affected
pregnancies [38]. Maternal vitamin D deficiency during
pregnancy was associated with impaired lung
development in 6-year-old offspring; neurocognitive
difficulties at the age of 10, an increased risk of eating
disorders in adolescence, and lower peak bone mass
at the age of 20 after relevant covariates were
adjusted. Randomised controlled trials with long-term
follow-up of offspring are required to examine
beneficence for offspring and to determine the optimal
level of maternal serum 25(OH)D for fetal
development [39].
Optimal Vitamin D level is also essential from
the adolescent years until the old age that is needed
for health benefits. Serum Vitamin D levels decline
with puberty onset, and holds a higher risk for obesity,
and much greater for Insulin Resistance in prepubertal children with suboptimal Vitamin D serum
levels [40, 41]. Hypovitaminosis D in overweight or
obese adults is registered in many studies, usually
13
accompanied with other health conditions. Mice on
high-fat diet and low-fat diet was treated with calcitriol

to demonstrate its effectiveness in reducing obesityassociated renal abnormality. Suggested mechanism
was through reduction of cytokines, such as Toll-like
Receptors (TLR) that are down-regulated by Vitamin
D, hence reducing Interleukin-6 (IL-6) or by preventing
abnormal growth of parathyroid hormone (PTH). The
lipid droplets were found to be in a degenerative stage
in mice fed High-Fat-Diet (HFD) with calcitriol
treatment, which showed a causal relationship
between calcitriol intake in renal tubules causing
structural changes under HFD conditions [42]. A study
that included people above 65 years of age suggested
an increased risk of vitamin D deficiency in overweight
and higher body fat percentages [43]. As previously
mentioned, studies also support an inverse
relationship between weight loss and Vitamin D serum
changes. This is shown to be effective in eliminating
obesity-related
inflammation
since
significant
reductions in levels of IL-6 were noted with
intervention combining Vitamin D3 supplementation
and weight-loss program [44]. Low serum 25(OH)D
was found to be significantly associated with high
serum IL-6 in overweight/obese children and with
increased hs-CRP in obese children [45].
1,25(OH)2D3 is also found to have a strong inhibitory
effect on NFκB signalling in human adipocytes [46].
On the contrary, a meta-analysis conclusive of 13
RCT suggests that Vitamin-D supplementation does
not affect inflammatory markers: CRP, TNF-a, IL-6 in
overweight or obese subjects [47]. Some studies do
not support any link between Vitamin D
supplementation and obesity. Supplementation
with vitamin D showed no effect on adiposity
measures in adults [48]. An increase in serum levels
of 25OHD or other inflammatory markers was not
observed in overweight and obese youths with
150,000IU supplemented every 3 months, which
demands investigation regarding potential dosage and
frequency, [49] since another trial with dosage as low
as 400IU up till 4800IU daily yielded serum changes
when administered for 12 months [50].

Role of Vitamin D in other obesity
mediated diseases
Chronic diseases are usually linked with
obesity, which has been further explored in relation to
Vitamin D status or to investigate the effectiveness of
supplementation in attenuating related symptoms.
Visceral obesity has been also found to be related
with low levels of Vitamin D [51]. Visceral obesity is
also highly correlated with Non-Alcoholic Fatty Liver
disease (NAFLD) thus it is expected that Vitamin D is
also related with NAFLD. A recent study in adults
demonstrated the strong link between vitamin D and
NAFLD [52]. The authors examined a total of 1081
adults and concluded that low vitamin D levels were
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highly associated with NAFLD independent of visceral
obesity in subjects with Diabetes or insulin resistance
[52]. BMI was also strongly associated with plasma
25- hydroxy Vitamin D, [25(OH)D] and PTH
concentrations with possible influence of plasma
25(OH)D in the pathogenesis of hypertriglyceridemia
and atherogenic dyslipidemia through inflammation,
because the association disappeared when uCRP
(ultrasensitive C-Reactive Protein) was introduced as
covariable [53]. 25(OH)D low levels and unfavourable
lipid patterns have been also found in children [54].
No effect on β-cell function or insulin action in obese
non-diabetic adolescents was observed upon
administration of Vitamin D3 supplementation [55]. A
systematic review provides evidence of the
insignificant effect of supplementation with vitamin D
on glucose and insulin metabolism in overweight and
obese individuals but a positive influence on the
serum concentration of 25(OH)D [47]. Serum
25(OH)D level in diabetic patients (Type 2) was found
to be inversely correlated with monocyte adhesion to
endothelial cells. 1,25(OH)2D3 suppressed ER stress,
[56] and promoted M1-predominant phenotype with
lower endothelial adhesion. Vitamin D suppresses
both subsets of monocytes, with M1 predominant,
however, M1 is involved in advanced plaques
compared to M2 in early stages in simple terms [57].
Real paradigms might be more complex and needs
further research. A decrease in systolic blood
pressure and adiposity in middle-aged subjects after a
weight-loss intervention was observed with an
increase in plasma 25(OH)D level [58]. Lower
inflammatory profile, better insulin sensitivity, higher
Vitamin D levels and IGF-1 (Insulin-like Growth
Factor-1) in lean mass of obese patients recorded in
the study suggest physical activity programs potential
to create a better metabolic profile [59]. Hence,
special programs to support a lifestyle that incorporate
dietary changes and physical activity programs can be
used to attain better Vitamin D levels with a range of
other health benefits.
In addition, visfatin has been recently found to
be associated with Vitamin D levels. Visfatin is a new
adipokine involved in several processes. Visfatin plays
an important role in inflammatory processes [60]. In a
very recent study [61], the authors examined 50
patients with chronic hepatitis with elevated visfatin
levels. After administration of vitamin D3 (15,000
IU)/weekly, the patients’ visfatin levels were
significantly reduced after a 12, 14, and 48-week
period compared with the baseline data. The
researchers
concluded
that
Vitamin
D
supplementation may offer beneficial effects in
reducing inflammation in these patients. More studies
though are needed to elucidate these optimal effects.
In conclusion, the latest research on Vitamin
D deficiency and obesity pandemic supports the role
for Vitamin D in prevention and occurrence of obesity.
Hence, public health sector needs to address the
implying socio-economic aspects influencing Vitamin

D status in order to prevent the burden of the disease
which the possibly an outcome of Vitamin D
deficiency. The adipokines secretion and inflammatory
cytokines expression are importantly linked to Vitamin
D metabolism. However, the mechanisms need
further elucidation, as research is both equivocal and
inadequate to establish a direct relationship in some
cases. The role of visceral fat is stronger compared to
subcutaneous fat in inflammation, related to obesity.
The clinical trials identified in this paper usually
involve Vitamin D supplementation in attaining
sufficient Vitamin D levels, which indicates the need
for trials to determine if same effects of Vitamin D can
be observed with dietary sources too, as it is
imperative in deciding on fortification of food across
different socio-economic groups.
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